Community and Leadership Programme Committee (CLPC)
Christoforos Mallouris, UNAIDS, International Co-Chair
Read the bio
Chris Mallouris works as the Community Mobilization Adviser at UNAIDS, Geneva. His work includes integration of community responses into national AIDS plans, good policy and practice, meaningful engagement of key populations, including people living with HIV, and acts as the UNAIDS focal point on people who inject drugs. Before joining UNAIDS, Chris worked as a consultant for the Social Justice 4 All consulting firm (2012-2013) and was the Director of Programmes at the Global Network of People Living with HIV (GNP+; 2008-2011), during which time he oversaw and managed all programmatic and advocacy work of the organization. He was with UNESCO (Paris) from 2003 to 2008, working on the education's sector response to AIDS. Chris holds a Bachelors of Art in Physics from Macalester College (1995), a Masters and a Ph.D. in Astrophysics from the University of Chicago (1996, 2001) and a Postgraduate Diploma in Public Health from the London School of Hygiene and Tropical Medicine External Programme (2009).
Louise van Deth, The Netherlands, Local/Regional Co-Chair
Read the bio
Louise van Deth is executive director of Aids Fonds and Soa Aids Nederland. She has been with this organisation since 2008. Before that she was director of an environmental NGO. She started her career as in investment banker in the Netherlands. Louise van Deth served on the board of many private foundations. Currently she is chair of the audit committee of the FNV, the largest labour union in the Netherlands. She is also on the board of Funders Concerned About Aids. Louise hold an MBA from Tuck Business School and a Master’s degree in English literature from the University of Amsterdam.
Michel Kazatchkine, Switzerland, Leadership Co-Chair
Read the bio
Professor Michel Kazatchkine has spent the last 30 years fighting AIDS as a leading physician, researcher. administrator, advocate, policymaker, and diplomat. He attended medical school at Necker--‐Enfants--‐Malades in Paris, studied immunology at the Pasteur Institute and completed postdoctoral fellowships at St Mary’s Hospital in London and Harvard Medical School. Professor Kazatchkine has played key roles in various organizations, including serving as Director of the National Agency for Research on AIDS (ANRS) in France (1998--‐2005) and Chair of the WHO’s Strategic and Technical Committee on HIV/AIDS (2004--‐2007). From 2005 to 2007, Professor Kazatchkine served as French Ambassador for the fight against HIV/AIDS and Communicable Diseases. In 2007, he was elected Executive Director of the Global Fund, a position in which he served until March 2012. In July 2012, Professor Kazatchkine was appointed as the UN Secretary--‐General’s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia. He is a Senior Fellow with the Global Health Program of the Graduate Institute for International and Development Studies in Geneva, a member of the Global Commission on Drug Policy and serves as Chair of the Board of the Robert Carr Civil Society Networks Fund.
Gennady Roshchupkin, Estonia
Read the bio
Openly living with HIV and being a PLWHIV and gay community activist since 1991, Gennady is a co-founder of and Technical Support Coordinator of the Eurasian Coalition on Male Health (ECOM), which currently unites more than 50 MSM/LGBT organizations and activists in Eastern Europe and Central Asia. Gennady is a member of ITPC and EHRN. In 2008, he became a member of the Regional expert group on work with MSM in EECA. His expertise includes the development and empowerment of community networks, planning and provision of technical support to various stakeholders, BCC programs, HIV and STIs prevention and social support, and M&E of social projects and initiatives. He has published several articles and brochures on social support to PLWHIV and adherence to treatment, and acting as either a co-author or reviewer, took part in the development of at least 20 training modules on NGO management, VCT, BCC, social and psychological support to PLWHIV, and community empowerment.
Georgina Caswell, UK
Javier Bellocq, Argentina
Read the bio
Javier began working in HIV in 1988 in Buenos Aires, Argentina, and is a founding member of the Argentinean and Latin American PLWHA Network. Since having served in the board of GNP+ from 1995 to 2000, Javier has served in many international and regional boards, committees and working groups; such as the UNAIDS Program Coordinating Board and the Global Fund Board. Currently, Javier works as the Civil Society Representative in the CFATM LAC Board Delegation, and is a member of the Robert Carr Civil Society Network Fund International Steering Committee.
Lilianne Ploumen, The Netherlands
Ludo Bok, USA
Read the bio
Ludo Bok is the Team Leader, Development Effectiveness of the UNDP HIV, Health and Development Group, and current acting as UNDP Global Coordinator for the Joint United Nations Programme on HIV/AIDS (UNAIDS). He leads the collaborative process of policy development in relation to UNAIDS, and the HIV and Health related dimensions of the 2030 Agenda for Sustainable Development. Mr. Bok has worked on global health and development for 20 years at the United Nations and in civil society, and has worked in Africa, Asia and Europe. Before joining UNDP, he worked for the UNAIDS Secretariat in a number of positions in Viet Nam, Switzerland, Lesotho and Zimbabwe. Before joining UNAIDS, Ludo worked for the African Medical and Research Foundation (AMREF) in Tanzania and the External Relations department of the Radboud University Nijmegen. A Dutch national, Mr. Bok holds a Master’s degree in Development Studies from the Radboud University Nijmegen, and a post-graduate certificate in cross-sector partnership from Cambridge University.
Read about the programme committee's vision
The AIDS response has yielded tremendous successes, but it has also demonstrated the staggering amount of work that remains to reach all people in need of treatment and to establish prevention services that are accessible, affordable, acceptable, equitable and grounded in human rights.
Reaching almost half of the 36.7 million people living with HIV with antiretroviral therapy is impressive and must be celebrated. However, 18 million people living with HIV are still not accessing treatment, and TB remains the leading cause of death among people living with HIV. Today, the tools to end the epidemic are available, and so is the evidence that they are effective. This tools include treatment, a broad range of prevention interventions, harm reduction, enabling legal environments, health and community systems that work together. However, it is of utmost importance to understand the barriers – systemic weaknesses, social and societal attitudes, punitive laws, policies and practices, financial limitations and restrictive political spaces – that leave half of people living with HIV and people at risk of HIV without the services required to bring an end to AIDS as a public health threat.
The political environment and development priorities are changing rapidly. Ending the AIDS epidemic is imperative in meeting the Sustainable Development Goals (SDGs). The universal and integrated nature of the 2030 Development Agenda, as well as the ambition to leave no-one behind, will require social movements, development sectors and scientists to work together to achieve the SDG goals.
In preparing for AIDS 2018, the Community & Leadership Programme Committee will work towards a new and renewed leadership for an AIDS response and for a transformation in the way we work: the way resources are used, the way funding mechanisms are constructed and accessed, the way evidence is applied, and the way we keep each other accountable and respond to inequities.
At AIDS 2018, demonstrating what works will not be enough. We must call out what is not working and where we must engage differently to advance human rights, involve communities meaningfully as decision makers, and abolish disempowering legal and policy environments, discrimination and marginalization.
The CLPC will also drive a “community” of new leadership that supports the greater involvement of people living with HIV and affected communities and that draws from the political arena, private sector, researchers and other stakeholders who have great influence to mobilize the human and financial resources and political will needed to end the AIDS epidemic. The CLPC will drive thought-provoking discussions on how to convince decision makers at international, national and local levels to work in solidarity to fully fund the AIDS response.
The CLPC envisions AIDS 2018 to be a unique opportunity to highlight the achievements and gaps in reaching treatment, prevention and human rights goals. It is also a unique opportunity to embed the AIDS response within a broader political and development agenda, demonstrating that neither AIDS nor other development goals can be reached without advancing gender equality, promoting peaceful and inclusive societies, promoting innovations, and addressing the underlying vulnerabilities of key populations at the systemic and societal levels.
The CLPC will work towards a conference of equals, reinvigorating leadership from all sectors, and supporting and empowering new leaders from all walks of life. This will be a conference that puts community priorities at the centre, reaffirms equity principles, builds bridges across social movements, and takes the greater and meaningful involvement of communities to the next level. This will be an all-embracing conference that creates space and opportunity for everyone, including people living with HIV, people who use drugs, men who have sex with men, sex workers, transgender people, prisoners and people in closed settings, displaced populations, women and girls, and young people.
The CLPC strives to ensure that the programme of the 22nd International AIDS Conference advances knowledge, strengthens unity and proposes transformations through open and dynamic dialogue between communities affected by HIV, political leaders, service providers, the private sector and scientists.
Scientific Programme Committee (SPC)
James Hakim, Zimbabwe, IAS Co-Chair
Read the bio
James Hakim is Professor of Medicine; formerly Chair of Medicine at the University of Zimbabwe College of Health Sciences. In addition, he is the Director of the UZ Clinical Research Centre and a Co-PI in the UZ-UCSF Collaborative Research Program, two programs which are involved in HIV/AIDS research including antiretroviral therapy, prevention, opportunistic infections and perinatal HIV. James is also the Principal Investigator of the UZ Medical Education Partnership Initiative-NECTAR, a PEPFAR and NIH funded programme (2010-2016), whose goal is to improve medical education capacity and research capacity strengthening to cope with the heavy burden of all diseases, especially HIV/AIDS in Africa. James Hakim trained at Makerere University, Uganda (MBChB); University of Nairobi, Kenya (MMed-internal medicine); Royal Colleges of Physicians UK (MRCP-UK); University of Newcastle, Australia (MMedSci-Clinical Epidemiology); University of Cape Town (Health Professions Education) and completed a post-doc in Cardiology at Aachen, Germany. He is also a fellow of the Royal Colleges of Physicians of London and Edinburgh. Recently, James Hakim was nominated for an award of a Doctor of Science in Medicine from University College London at a graduation ceremony in July 2016.
Sheena McCormack, UK, Local/Regional Co-Chair
Read the bio
Sheena McCormack, MBBS, MSc, FRCP, Dip Ven., is a Clinical Epidemiologist who has been coordinating HIV prevention trials since 1994, when she joined what subsequently became the Medical Research Council Clinical Trials Unit. From the outset she has worked on HIV vaccine trials, all Phase I/II, in Europe and Africa. Since 1998 she has been involved in microbicide trials and was Chief Investigator of a Phase III vaginal microbicide trial that enrolled 9,385 women through six research centres in Southern Africa. Sheena has been a Consultant in HIV/GU Medicine since 1991, initially at the Royal Devon and Exeter Hospitals and since 1996 at Chelsea & Westminster Hospital working at the Dean Street clinic in Soho. She recently reported the PROUD PrEP study conducted in gay and other men who have sex with men which showed a very high level of effectiveness for daily oral Truvada in the real world setting of 13 sexual health clinics in England. PROUD was the first HIV prevention trial to use a randomization to immediate or deferred access in order to compare PrEP to no-PrEP and assess the impact on risk behavior and determine if any change in this would undermine efficacy. Although her primary current focus is to ensure that PrEP becomes available to those who need it in the UK and Europe, she continues to work on HIV vaccine trials and maintains an interest in microbicides. Sheena became a Professor of Clinical Epidemiology at Imperial College in August 2012, and joined UCL in August 2013 when the MRC Clinical Trials Unit became part of UCL.
Wafaa El Sadr, USA, International Co-Chair
Read the bio
Wafaa El-Sadr is University Professor of Epidemiology and Medicine and Mathilde Krim-amfAR Professor of Global Health at Columbia’s Mailman School of Public Health and College of Physicians and Surgeons. Through ICAP at Columbia University, the Center she established more than a decade ago, she was instrumental in support of establishment of large-scale programs in sub Saharan Africa and Asia that integrate research, education, training and practice. ICAP works closely with US government agencies, international organizations, academic institutions, private sector, community-based organizations and civil society groups in the pursuit of responsive, inclusive, sustainable and innovative approaches to addressing global health threats and achieving public health impact. ICAP supports the education, training and mentorship of diverse workforce for health with a special emphasis on support for the nursing workforce. Dr. El-Sadr’s research interests are diverse and include research on the prevention and treatment of HIV, tuberculosis, non-communicable diseases, maternal-child health among others. She received her medical degree from Cairo University, a Master’s in public health from Columbia’s Mailman School of Public Health and a Master’s in public administration from Harvard University’s Kennedy School of Government. She was named as McArthur fellow and is a member of the National Academy of Medicine.
Huldrych Günthard, Switzerland, Local/Regional Co-Chair
Sharon Lewin, Australia, International Co-Chair
Read the bio
Sharon Lewin is the inaugural director of the Peter Doherty Institute for Infection and Immunity, a joint venture between the University of Melbourne and Royal Melbourne Hospital. She is Professor of Medicine at The University of Melbourne and a consultant physician at the Alfred Hospital, Melbourne, Australia. Her research focuses on understanding why HIV persists on treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection, and has published over 230 manuscripts. She is passionate about research translation and science communication, and the role of community in research and health. She was the local co-chair of the 20th International AIDS Conference (AIDS2014), the largest health conference ever held in Australia. She is an elected member of the governing council of the International AIDS Society and on the leadership team of the IAS Towards a Cure initiative. In 2014, she was named Melburnian of the Year.
Karine Lacombe, France, Local/Regional Co-Chair
Read the bio
Professor Karine Lacombe currently holds the position of Associate Professor in the Infectious and Tropical Diseases department of Saint-Antoine Hospital (AP-HP), in Paris, France. She teaches Infectious Diseases and Public Health in numerous universities and schools around France, Sub Saharan Africa and Asia. She is involved in the clinical and therapeutical management of HIV-infected patient care, at the inpatient and outpatient clinic of AP-HP. She has developed clinical research programmes in Europe, Sub-Saharan Africa and Vietnam on the issues of HIV-chronic hepatitis B and C, as well as co-morbidities associated with the use of antiretrovirals. She acts as member of the European AIDS Clinical Society Guidelines group, the French Committee and the World Health Organization’s guideline development groups in HIV and Hepatitis. She is involved in the UNAIDS Experts Panel for providing guidance on the global response to HIV.
Roy Gulick, USA, International Co-Chair
Read the bio
Dr. Roy Gulick is Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Cornell Medicine, and Attending Physician at the New York Presbyterian Hospital in New York City. Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention, and assessing antiretroviral agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG), and the HIV Prevention Trials Network (HPTN), sponsored by the U.S. National Institutes of Health. He also serves as the Co-Chair of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection, Chair of the NIH Office of AIDS Research Advisory Committee (OARAC), and a Board Member of the International Antiviral Society-USA. He has presented at national and international meetings and published widely.
Caroline Sabin, UK, Local/Regional Co-Chair
Read the bio
Caroline Sabin, PhD, is Professor of Medical Statistics and Epidemiology at University College London (UCL), and is Director of the National Institutes for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections. Over the past 25 years, Prof Sabin has worked on the analysis of large observational HIV databases with a particular interest in raising awareness of the biases inherent in these databases – her particular interests are in describing the natural history of HIV infection, identifying prognostic markers and describing responses to cART (including adverse events). She established, and is the principal investigator on the UK Collaborative HIV Cohort (UK CHIC) Study, and since 2001, she has been the principal statistician for the D:A:D Study. More recently, she has been the co-PI on the POPPY Study, a new cohort to study the effects of ageing in HIV Infection. She has been closely involved with many other large HIV cohort studies and collaborations, both in the UK and abroad.
Nittaya Phanuphak, Thailand, International Co-Chair
Read the bio
Nittaya Phanuphak is currently the Chief of the Prevention Department at the Thai Red Cross AIDS Research Centre (TRCARC) in Bangkok, Thailand. She joined the TRCARC in 2002 to lead a country-wide prevention of mother to child transmission (PMTCT) operational study. She has a deep interest in HIV prevention and key populations (KP), especially around the use of Community-Led Health Service (CLHS) approaches to enhance access to HIV testing, prevention and treatment. She started the country’s first Test and Treat Study among 800 Thai MSM and transgender women in 2012. She currently works actively with community and government partners to establish a national technical assistance platform to support the accreditation and legalization of the CLHS model to ensure its sustainability through domestic a financing mechanism.
Catherine Hankins, The Netherlands, Local/Regional Co-Chair
Read the bio
Catherine Hankins MD MSc PhD FRCPC CM is Deputy Director, Science and Scientific Chair of the annual African INTEREST conference, Amsterdam Institute for Global Health and Development. She is Professor of Public and Population Health, Faculty of Medicine, McGill University and Honorary Professor at the London School of Hygiene and Tropical Medicine. She chairs the Scientific Advisory Board of CAPRISA, KwaZulu-Natal, and the USA National Institutes of Health’s, HIV Prevention Trials Network’s Scientific Advisory Group. She was principal investigator of studies involving women, prisoners, and people who inject drugs, and of population-based epidemiological studies, before joining UNAIDS in 2002, as Associate Director and Chief Scientific Adviser. She was the editor of the popular UNAIDS’ science blog HIV This Week, a trustee of the UK HIV Research Trust and member of the International AIDS Society Industry Liaison Forum. She was named to the Order of Canada in 2013.
Maksut Kulzhanov, Kazakhstan, International Co-Chair
Read the bio
Dr Maksut Kulzhanov is a trained physician and scientific researcher. He has acted as Deputy Director of Scientific Research at the Institute of Hygiene, and Head of the Department of Health Planning and Forecasting. He has served as the Deputy Minister of Health, responsible for science, education, economy, finance and health care reform, Rector of Kazakhstan School of Public Health, and Director General of the Republican Center of Health Development. He is currently Professor of the Kazakhstan School of Public Health, and Advisor to the Minister of Health.
Charlotte Watts, UK, Local/Regional Co-Chair
Read the bio
Professor Charlotte Watts PhD FMedSci is Chief Scientific Adviser to the Department for International Development, where she is Director of the Research and Evidence Division. Charlotte is seconded from the London School of Hygiene and Tropical Medicine, where she is a Professor in Social and Mathematical Epidemiology. She is a global expert on HIV and on violence against women, with her work over the past twenty five years spanning analyses of the social, economic and gendered determinants of HIV risk, mathematical modelling of disease trajectories, intervention design and evaluation, economic evaluation and co-financing approaches. Charlotte has a PhD in mathematics from the University of Warwick, is a Fellow of the Academy of Medical Sciences, and foreign associate member of the US National Academy of Medicine. She has published over two hundred publications, led large research programmes, and supervised PhD students.
Jonathan Gunthorp, South Africa, International Co-Chair
Read the bio
Jonathan Gunthorp is the Executive Director at the Southern African AIDS Trust (SAT). He overseas SAT’s strategy based on four pillars: Sexual and reproductive health and rights (SRHR) interventions for girls, adolescents and young women; gender equality & empowering girls; data for health; and civil society participation in comprehensive & resilient systems for health. Jonathan works with the UNAIDS PCB NGO Delegation on issues of funding for civil society; and is concerned in southern Africa with issues of the sustainability and resilience of systems for health under the onslaught of population growth and NCDs. Jonathan has lead programmes in health, HIV and SRHR for nine years. He previously worked in national skills development, TVET systems and higher education governance.
Read about the programme committee's vision
Science to guide management and policy
AIDS 2018 will deliver the latest evidence to guide HIV prevention, clinical management, policy, investment and programming. In times of constrained resources, decisions must be informed by excellent science and pragmatic considerations. Drugs developed for HIV treatment also work for HIV prevention. To fully realize their potential for individuals and for populations, there is a need to scale up access, reach all populations, including vulnerable and key populations, and seize the opportunity to tackle other health threats that may affect persons living with HIV or at risk of HIV infection. By monitoring impact, course corrections can be made nimbly, and steps taken to ensure engagement of individuals in long-term care, helping to achieve individual and population benefit while avoiding drug resistance.
AIDS 2018 will also be a forum for sharing updates on new prevention methods and on the implementation of combination prevention strategies that are aimed at reducing the number of new HIV infections. The conference will demonstrate how surveillance and cohort data will further our understanding of the trajectory of the epidemic. These data continue to inform priority populations for testing and prevention services, as well as the introduction of new diagnostics and therapeutic agents that have been shown to be effective in clinical trials, including those for co-infections and co-morbidities.
AIDS 2018 will identify important information, programming and financing gaps by region and by population, determining in partnership with affected populations how best to harness advances in service delivery methods, innovations, technology and data systems to advance progress towards the end of the HIV epidemic.
Investment with a long-term view is needed
AIDS 2018 will inject a reality check with respect to elimination of HIV in the era of the Sustainable Development Goals (SDGs) set by the United Nations. The journey to a cure or to a preventative vaccine is complex and will likely encounter successes, as well as setbacks; it requires investment, innovation and sustained commitment. Investment is also needed to ensure that people remain uninfected, and that all people with HIV have access to the care and treatment they need in order to live long and live well. The many people acquiring HIV each year are joining the millions of people living with HIV who are ageing. Adolescents and young people in some regions of the world continue to experience the brunt of the HIV epidemic, and they need to be able to make happy, healthy and safe sexual and reproductive choices.
As populations have become more mobile through choice or force, social disruption and sexual mixing are creating new HIV transmission networks. AIDS 2018 will highlight the risk that lack of access to needed services poses for migrant populations and the population in the host countries that they seek shelter in, and will report best practice. AIDS 2018 will demonstrate the ongoing need for sustainable investment in programming gaps if community and civil society responses are to be integrated within resilient systems for equitable and inclusive health over the coming decade.
Leveraging available resources to maximize impact
AIDS 2018 will focus on efficient and cost-effective strategies to reduce HIV risk and expand access to HIV prevention tools and antiretroviral treatment, respecting the choices, psychosocial needs and overall priorities of the target populations. The conference will aim for a holistic approach to integrated responses and integrated care through synergy across civil society groups and fostering collaborations across the various sectors, especially in tackling issues related to young people, women, transgender populations, and those who are displaced, incarcerated, experiencing mental health issues, or subject to stigma and discrimination.
The conference will explore peer-led strategies that reach those in need when and where it is convenient. It will formally acknowledge the key role of community healthcare workers and peer educators in community mobilization, engagement and retention in health programmes. AIDS 2018 will highlight national strategies for scale up of public health services that have taken an innovative approach to sustainable financing for programmes.